AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody by partner Genentech Multiple other products progressing, key appointments made to …